Skip to main content

Table 5 LCM output parameters

From: Alignment of preferences in the treatment of multiple myeloma – a discrete choice experiment of patient, carer, physician, and nurse preferences

 

Class 1

Class 2

Class Proportions

0.61

0.39

Utility parameters

Parameter

T-Ratio

Parameter

T-ratio

Generic parameters

 Subcutaneous - high frequency

(Reference category: oral)

−0.899*

−3.380

− 0.802*

−4.800

 Subcutaneous - low frequency

(Reference category: oral)

−0.899*

−3.380

0

0

 Intravenous - high frequency

(Reference category: oral)

−0.940*

−3.470

− 0.753*

− 4.380

 Intravenous - low frequency

(Reference category: oral)

− 0.940*

− 3.470

− 0.514*

− 3.110

 Out of pocket cost

− 0.012*

−2.400

−0.017*

− 4.140

 Overall survival

1.226*

8.670

0.291*

9.440

 Short remission period

(Reference category – long remission period)

−1.059*

−5.860

−0.750*

−5.440

 Mild side effects

−0.009*

−2.230

−0.009*

− 2.890

 No severe side effects

(Reference category – some severe side effects)

1.251*

3.930

0.644*

3.960

 Neither treatment constant

−2.294*

−3.390

−0.710*

− 3.020

Interaction effect parameters

 Out of pocket costs (Carers)

(Reference category – out of pocket costs – people living with MM)

0

0

0

0

 Out of pocket costs (Physicians)

(Reference category – out of pocket costs – people living with MM)

0

0

−0.033*

−2.240

 Out of pocket costs (Nurses)

(Reference category – out of pocket costs – people living with MM)

0

0

−0.064*

−3.780

 Overall survival (Carers)

0

0

0.108*

2.490

 Overall survival (Physicians)

0

0

0.449*

4.120

 Overall survival (Nurses)

−0.468*

−2.970

0.439*

4.250

 Short remission period (Carers)

(Reference category – long remission period – people living with MM)

−1.366*

−2.770

0

0

  1. *p < .05, Restricted log likelihood: − 2405.961, Log likelihood: − 1022.241, Rho-squared: 0.452, Number of respondents: 219, Number of choice observations: 2190